Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort

Seminars in Arthritis and Rheumatism - Tập 50 - Trang 915-922 - 2020
Mohammad Movahedi1,2, Elliot Hepworth3, Reza Mirza4, Angela Cesta1, Maggie Larche5, Claire Bombardier1,6,7
1Ontario Best Practices Research Initiative, Toronto General Research Institute, University Health Network, Toronto, ON, Canada
2Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada
3Division of Rheumatology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
4Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
5Divisions of Rheumatology and Clinical Immunology and Allergy, Departments of Medicine and Pediatrics, McMaster University, Hamilton, ON, Canada
6Department of Medicine (DOM) and Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada
7Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Seminars in Arthritis and Rheumatism

Tập 50

915-922

Thông tin tác giả